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(30mL/min/1.73m2≤GFR<60mL/min/1.73m2) in the CILON-T trial. Patients with
decreased renal function were more anemic, diabetic and hypertensive. In addition,
they had more severe angina and previous history of percutaneous coronary
intervention. Baseline PRU and P2Y12 % inhibition did not different between two
groups. At six months follow-up, patients with renal dysfunction showed higher PRU
(330.4±57.2 vs. 312.4±66.3, p=0.005) and lower P2Y12 % inhibition (26.2±20.5% vs.
30.9±25.9%, p=0.029). In the subgroup analysis of patients with renal dysfunction,
patients treated with TAT (n=98) showed more platelet inhibition than those with DAT
(n=96) (PRU: 334.7±58.4 vs. 325.9±56.0, p=0.379; P2Y12 % inhibition: 30.5±20.4%
vs 21.8±19.8%, p=0.013). There were no differences in the interval change of GFR
between two groups (TAT: 52.2±7.2 vs. 53.5±12.1, p=0.071; DAT: 53.2±5.9 vs.
54.7±10.6, p=0.928; between two groups: p=0.376).
Conclusion: Patients with moderate renal dysfunction showed significantly lower
responsiveness to clopidogrel at six months. The treatment of cilostazol on top of
clopidogrel significantly improved the P2Y12 inhibition without deterioration of renal
function.
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Background: Impaired renal function is associated with reduced responsiveness to
clopidogrel. There is no study to overcome platelet hyporesponsiveness in CKD
patients. The purpose of this study was to determine the functional impact of cilostazol
in patients with chronic kidney disease (CKD) undergoing hemodialysis.
Methods: A total of 63 patients with CKD undergoing hemodialysis were enrolled.
Patients were randomly assigned to receive either a daily dose of 75 mg of clopidogrel
(group 1, n = 21) or a daily dose of 150 mg (group 2, n = 22) or a daily dose of 75 mg
of clopidogrel with 200mg of cilostazol (group 3; n = 20) for 14 days. Another 22
patients with normal renal function undergoing PCI were treated with 75 mg of
clopidogrel for control group. Platelet function and activation markers were assessed
before and after antiplatelet agents.
Results: Baseline platelet function measurements were similar in 3 groups. But CKD
group showed significantly higher platelet aggregation compared with control groups.
After 14 days, the maximal inhibition of platelet aggregation was 19.0 ± 9.8 % in the
group 1, 17.5 ± 9.9 % in the group 2, and 38.1 ± 14.4 % in the group 3 (p < 0.05). The
VerifyNowTM P2Y12 assay also indicated lower P2Y12 reaction units in group 3
(240.6 ± 59.6) than group 1 (317.9 ± 42.6) or group 2 (304.3 ± 67.3) (p < 0.01). The
rate of high on-treatment platelet reactivity was significantly lower in group 3 than in
1 and 2 groups (10% vs 43% vs 32%, respectively, p < 0.05). After treatment, the
changes of plasma sCD40L and sP-selectin levels were significantly higher in group 3
compared with group 1 and 2 (p < 0.01). But increase of the clopidogrel maintenance
dose from 75 to 150 mg did not show significant differences of platelet function and
activation markers.
Conclusion: Adjunctive cilostazol improves platelet inhibition as compared with
conventional or high maintenance dose of clopidogrel in patients with CKD undergoing
hemodialysis.
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Background: Current guidelines suggest dual antiplatelet therapy (DAPT) for a
minimum of 12 months after PCI with a drug-eluting stent (DES). However, the
optimal duration of DAPT in patients with chronic kidney disease (CKD) remains
ambiguous given that these patients have an increased risk of both thrombotic and
bleeding events. Therefore, we sought to investigate the association between the
duration of DAPT and adverse cardiovascular events in patients with CKD who
received PCI.
Methods: 653 patients were selected from wave 4 (2004) and wave 5 (2006) of the
NHLBI Dynamic Registry who had an estimated glomerular filtration rate < 60ml/min.
A landmark analysis was performed on all patients who were event free at 12 months
after their index PCI with DES implantation, and they were stratified by whether they
were still on DAPT or not. All patients were followed for three years after that for the
occurrence of cardiovascular events.
Results: Of the 653 patients, 438 (67%) were on DAPT and 215 (33%) were not on
DAPT at 1 year. The mean age, prevalence of DM, HTN, and PAD were similar
between the two groups. Patients on DAPT at 1 year were more likely to have their
index PCI to treat a MI, but less likely to have had GI bleeds, prior strokes, and to be
on warfarin, as compared to those not on DAPT at one year. At 4 years from their index
PCI, patients who stayed on a longer duration of DAPT had a lower rate of death
(16.0% vs 23.9%, p=0.0086) than those on a shorter duration of DAPT (figure). There
were no differences in rates of MI (5.3% vs 5.0%, p=0.84), repeat revascularization
(10.7% vs 7.5%, p= 0.16), and stent thrombosis (0.6% vs 0.0%, p=0.33) between the
two groups.
Conclusion: Our data suggests that in this high-risk population of patients with CKD
who undergo PCI with DES, that longer duration of DAPT is safe and probably
beneficial in improving long-term outcomes.
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Background: Chronic kidney disease (CKD) is associated with increased risk of
adverse cardiovascular events, including contrast induced nephropathy (CIN) after
percutaneous coronary intervention (PCI). But, prognostic significance of admission
serum creatinine for CIN and mortality in patients with ST elevation myocardial
infarction (STEMI) is not known. So, the aim of this study was to evaluate impact of
admission serum creatinine on cardiovascular death and CIN in patients with STEMI
underwent primary PCI.
Methods: We analyzed 328 consecutive patients with STEMI underwent primary PCI.
The patients were divided into two groups according to admission serum creatinine
level; group I: ≤ 1.2mg/dl (n=244, 74.4%), group II: > 1.2 mg/dL (n=84, 25.6%).
Contrast-induced nephropathy was defined as an increase in serum creatinine level
>25% or 0.5 mg/dL after 48 hours. We sought CIN and cardiovascular death at 12-
month follow-up.
Results: Baseline clinical characteristics were similar between the two groups. Group
II was associated with a significantly higher rate of CIN (8.4% vs. 26.9%, p < 0.001)
and cardiovascular death (6.6% vs. 18.8%, p = 0.01) compared with group I. At 12-
month follow-up, the death-free survival rate was lower in the group II compared with
group I (p <0.001). Also, when each serum creatinine group was divided according to
presensce of CIN, 12-month death-free survival was signicantly different between four
groups (log rank test p < 0.001)(Figure).
B135JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Contrast Nephropathy and Chronic Kidney Disease
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
